Trials / Sponsors / Quince Therapeutics S.p.A.

Quince Therapeutics S.p.A.

Industry · 10 registered clinical trials.

Status	Trial	Phase	Started
Terminated	Open-Label Extension of EryDex Study IEDAT-04-2022 Ataxia Telangiectasia	Phase 3	2024-12-11
Completed	Evaluate the Neurological Effects of EryDex on Subjects With A-T Ataxia Telangiectasia	Phase 3	2024-06-24
Terminated	Extension Treatment Using EryDex System in Patients With AT Who Participated in the ATTeST-IEDAT-02-2015 Study Ataxia Telangiectasia, Genetic Syndrome	Phase 3	2018-06-12
Completed	Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients Nervous System Disease, Genetic Syndrome	Phase 3	2017-03-02
Completed	Recovery and Survival of EryDex in Non-patient Volunteers Healthy	Phase 1	2015-01-01
Completed	International Ataxia Rating Scale in Younger Patients Ataxia Telangiectasia	—	2013-08-01
Completed	EryDex Pharmacokinetics in Healthy Volunteers Healthy	Phase 1	2013-06-01
Completed	Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Teleangiectasia Patients Nervous System Disorder, Genetic Syndrome	Phase 2	2011-02-01
Terminated	Intra-erythrocyte Dexamethasone Versus Placebo in Patients With Steroid-dependent Crohn's Disease Crohn's Disease	Phase 3	2009-06-03
Completed	Erythrocytes-Mediated Delivery Of Dexamethasone 21-Phosphate In Steroid-Dependent Ulcerative Colitis Ulcerative Colitis	Phase 2	2003-07-22